Affimed Presents Preclinical Data of Novel Innate Cell Engager AFM28 at the Annual Meeting of the European Hematology Association (EHA) June 10, 2022
Affimed Reports First Quarter 2022 Financial Results and Highlights Recent Operational Progress June 1, 2022
Affimed Highlights Trial Designs of Three AFM24 Ongoing Clinical Studies at the Annual Meeting of the American Society of Clinical Oncology (ASCO) May 26, 2022
Affimed to Report First Quarter 2022 Financial Results & Corporate Update on June 1, 2022 May 24, 2022
Affimed Presents Data on Innate Cell Engagers AFM24 and AFM28 at 19th Meeting of the Society for Natural Immunity May 16, 2022
Affimed to Present Preclinical Data Demonstrating Cytotoxic Activity of its Novel Innate Cell Engager AFM28 at the Annual Meeting of the European Hematology Association (EHA) May 12, 2022